Literature DB >> 22488635

Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer.

Lucía González1, Noemí Eiró, Luis O González, Alejandro Andicoechea, Esther Barbón, José L García-Muñiz, Francisco J Vizoso.   

Abstract

BACKGROUND: Matrix metalloproteases (MMPs) and their tissue inhibitors (TIMPs) are of crucial importance in the degradation of the stromal connective tissue and basement membrane components. Study of the behavior of these components might help to predict the aggressiveness of tumors. AIMS: To evaluate the expression and clinical relevance of MMPs and TIMPs for patients with resectable colorectal carcinoma.
METHODS: An immunohistochemical study was performed using tissue arrays and specific antibodies against MMPs-1, 2, 7, 9, 11, 13, and 14, and TIMPs-1, 2 and 3. Determinations were performed in cancer specimens from 104 patients with resectable colorectal cancer. The minimum period of follow-up was 12.5 years for patients without recurrence. To identify specific groups of tumors with distinct expression profiles, the data were analyzed by unsupervised hierarchical cluster analysis.
RESULTS: Expression of MMP-11 by fibroblasts and MMP-13 by tumor cells were associated with poor prognosis. The dendrogram revealed first-order division of tumors into two distinct MMP/TIMP molecular profiles, designated group 1 (n = 50) and group 2 (n = 54). Group 2 was characterized by significantly higher expression of MMP-1, 11, and 13, and TIMP-3.
CONCLUSION: Our results emphasize the prognostic value of MMP-11 and 13 expression in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488635     DOI: 10.1007/s10620-012-2154-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  59 in total

1.  Histopathological predictors of regional lymph node metastasis at the invasive front in early colorectal cancer.

Authors:  Yuri Akishima-Fukasawa; Yukio Ishikawa; Yoshikiyo Akasaka; Miwa Uzuki; Naomi Inomata; Tomoko Yokoo; Ryuga Ishii; Reiko Shimokawa; Kiyoshi Mukai; Hideko Kiguchi; Koyu Suzuki; Mieko Fujiwara; Kentaro Ogata; Hitoshi Niino; Hitoshi Sugiura; Akihiro Ichinose; Yoshikazu Kuroda; Daisuke Kuroda; Toshiharu Ishii
Journal:  Histopathology       Date:  2011-09       Impact factor: 5.087

2.  Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer.

Authors:  Dake Chu; Zhengwei Zhao; Yi Zhou; Yunming Li; Jipeng Li; Jianyong Zheng; Qingchuan Zhao; Weizhong Wang
Journal:  Ann Surg Oncol       Date:  2011-04-01       Impact factor: 5.344

Review 3.  Tissue inhibitor of metalloproteinases-1 in breast cancer.

Authors:  S Ø Würtz; A-S Schrohl; N Møller Sørensen; U Lademann; I J Christensen; H Mouridsen; N Brünner
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

4.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

5.  A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status.

Authors:  Christian Wittekind; Carolyn Compton; Phil Quirke; Iris Nagtegaal; Susanne Merkel; Paul Hermanek; Leslie H Sobin
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

6.  MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases.

Authors:  Riyad Bendardaf; Abdelbaset Buhmeida; Raija Ristamäki; Kari Syrjänen; Seppo Pyrhönen
Journal:  Scand J Gastroenterol       Date:  2007-12       Impact factor: 2.423

7.  Stromelysin-3 expression is an early event in human oral tumorigenesis.

Authors:  Shilpi Soni; Meera Mathur; Nootan K Shukla; Suryanarayan V S Deo; Ranju Ralhan
Journal:  Int J Cancer       Date:  2003-11-01       Impact factor: 7.396

8.  The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.

Authors:  Natalie Jeffery; Mairi H McLean; Emad M El-Omar; Graeme I Murray
Journal:  Histopathology       Date:  2009-06       Impact factor: 5.087

9.  Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.

Authors:  G I Murray; M E Duncan; P O'Neil; J A McKay; W T Melvin; J E Fothergill
Journal:  J Pathol       Date:  1998-07       Impact factor: 7.996

10.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1.

Authors:  V Noë; B Fingleton; K Jacobs; H C Crawford; S Vermeulen; W Steelant; E Bruyneel; L M Matrisian; M Mareel
Journal:  J Cell Sci       Date:  2001-01       Impact factor: 5.285

View more
  5 in total

1.  Toll-Like Receptor 4 and Matrix Metalloproteases 11 and 13 as Predictors of Tumor Recurrence and Survival in Stage II Colorectal Cancer.

Authors:  Noemi Eiro; Juan Francisco Carrión; Sandra Cid; Alejandro Andicoechea; José Luis García-Muñiz; Luis O González; Francisco J Vizoso
Journal:  Pathol Oncol Res       Date:  2019-02-01       Impact factor: 3.201

2.  Knockdown of inhibitor of growth protein 2 inhibits cell invasion and enhances chemosensitivity to 5-FU in human gastric cancer cells.

Authors:  Juan Zhong; Lei Yang; Ning Liu; Jun Zheng; Cong-Yao Lin
Journal:  Dig Dis Sci       Date:  2013-07-18       Impact factor: 3.199

3.  Relationship between Metalloprotease-7 and -14 and Tissue Inhibitor of Metalloprotease 1 Expression by Mucosal Stromal Cells and Colorectal Cancer Development in Inflammatory Bowel Disease.

Authors:  Antonio Altadill; Noemi Eiro; Luis O González; Alejandro Andicoechea; Silvia Fernández-Francos; Luis Rodrigo; José Luis García-Muñiz; Francisco J Vizoso
Journal:  Biomedicines       Date:  2021-04-30

Review 4.  The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer.

Authors:  László Herszényi; István Hritz; Gábor Lakatos; Mária Zsófia Varga; Zsolt Tulassay
Journal:  Int J Mol Sci       Date:  2012-10-16       Impact factor: 5.923

5.  Role of DDX3 in the pathogenesis of inflammatory bowel disease.

Authors:  Saritha Tantravedi; Farhad Vesuna; Paul T Winnard; Marise R Heerma Van Voss; Paul J Van Diest; Venu Raman
Journal:  Oncotarget       Date:  2017-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.